SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products....
relmacabtagene-autoleucel
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy p...
relmacabtagene-autoleucel
China's National Medical Products Administration (NMPA) has approved JW Therapeutics' investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in peo...
relmacabtagene-autoleucel